EUVIMEDEUVIMED entdecken
BeobachtungsstudieMultizentrische Studie

Treatment Patterns and Prognosis of Palliative Chemotherapy Combined With Targeting Agents in Patients With Unresectable Metastatic Colorectal Cancer: CHOICE, A Multicenter Longitudinal Observational Study

Jwa Hoon Kim, Yongjun Cha, Sang Joon Shin, Young Suk Park, Jung Hun Kang, Chan Kim, Sung Hee Lim, Myoung Joo Kang, Jong Gwang Kim, In Gyu Hwang, Jong-Kwon Choi, Seong Hoon Shin und 16 weitere

Anticancer Research · 2024

DOI: 10.21873/anticanres.16818 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Anticancer Research, 2024. Verfasst von Jwa Hoon Kim und 27 weiteren Autor:innen. Beteiligte Einrichtung: Division of Oncology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Republic of Korea. Hauptthemen laut MEDLINE: Colonic Neoplasms, Colorectal Neoplasms, Rectal Neoplasms. Die Arbeit wurde bisher 3-mal zitiert (Crossref).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND/AIM: This study investigated the treatment patterns and prognosis of patients with metastatic or unresectable colorectal cancer (mCRC) treated with chemotherapy with targeting agents. PATIENTS AND METHODS: This longitudinal multicenter study included 963 patients with mCRC who were treated in Korea between 2016 and 2020. Treatment patterns and efficacy were compared according to the mutation status and clinical factors. RESULTS: As first-line therapy, most of the patients (83.5%) received FOLFOX plus bevacizumab (35.4%), followed by FOLFIRI plus bevacizumab (18.8%), FOLFIRI plus cetuximab (17.0%), and FOLFOX plus cetuximab (12.3%). Bevacizumab was the most frequent agent (78.8%) combined with chemotherapy in RAS-mutated CRC, while cetuximab (57.2%) in RAS wild-type CRC. Cetuximab was frequently combined with a doublet regimen in patients with left-sided CRC than in those with right-sided CRC (34.4% vs. 16%). As second-line therapy, most patients (63.4%) also received doublet regimens with bevacizumab, and FOLFIRI plus aflibercept was administered in 15.1%. The objective response rate with FOLFIRI plus cetuximab was significantly higher in patients with left-sided CRC than in those with right-sided CRC (59.2% vs. 30.8%, p=0.008) and marginally higher in patients with RAS wild-type CRC than in those with RAS-mutated CRC (55.6% vs. 0.0%, p=0.092). Progression-free survival (PFS) with FOLFOX plus bevacizumab was significantly shorter than that with FOLFIRI plus bevacizumab (p=0.030) in RAS-mutated CRC, whereas there were no significant differences between regimens in RAS wild-type CRC. CONCLUSION: In patients with unresectable metastatic colorectal cancer, doublet chemotherapy with targeting agents is the most common therapy and efficacy depends on the mutation status as well as clinical factors.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Colonic NeoplasmsColorectal NeoplasmsRectal NeoplasmsHumansAntineoplastic Combined Chemotherapy ProtocolsBevacizumabCetuximabPrognosis

Stichwörter der Autor:innen

Colorectal cancerefficacymutation statusprimary tumor locationtreatment patterns

Substanzen

BevacizumabCetuximab

Autor:innen und Institutionen

  • Division of Oncology, Department of Internal Medicine, Korea University Anam Hospital, Korea University College of Medicine, Seoul, Republic of Korea.
  • Center for Colon Cancer, National Cancer Center, Goyang, Republic of Korea.
  • Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, Republic of Korea.
  • Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea.
  • Department of Internal Medicine, Gyeongsang University Hospital, Jinju, Republic of Korea.
  • Department of Medical Oncology, CHA Bundang Medical Center, CHA University, Seongnam, Republic of Korea.

Zitieren

APA

Kim, J. H., Cha, Y., Shin, S. J., Park, Y. S., Kang, J. H., Kim, C., Lim, S. H., Kang, M. J., Kim, J. G., Hwang, I. G., Choi, J. K., Shin, S. H., Kang, S. Y., Lee, S. C., Lim, S. T., Kim, J. S., Jeung, H. C., Kang, M. H., Choi, I. S., …, & Kim, Y. H. (2024). Treatment Patterns and Prognosis of Palliative Chemotherapy Combined With Targeting Agents in Patients With Unresectable Metastatic Colorectal Cancer: CHOICE, A Multicenter Longitudinal Observational Study. Anticancer Research. https://doi.org/10.21873/anticanres.16818

Vancouver

Kim JH, Cha Y, Shin SJ, Park YS, Kang JH, Kim C, et al. Treatment Patterns and Prognosis of Palliative Chemotherapy Combined With Targeting Agents in Patients With Unresectable Metastatic Colorectal Cancer: CHOICE, A Multicenter Longitudinal Observational Study. Anticancer Research. 2024. doi:10.21873/anticanres.16818

BibTeX
@article{Kim2024,
  author = {Kim, Jwa Hoon and Cha, Yongjun and Shin, Sang Joon and Park, Young Suk and Kang, Jung Hun and Kim, Chan and Lim, Sung Hee and Kang, Myoung Joo and Kim, Jong Gwang and Hwang, In Gyu and Choi, Jong-Kwon and Shin, Seong Hoon and Kang, Seok Yun and Lee, Sang-Cheol and Lim, Seung Taek and Kim, Jung Sun and Jeung, Hei-Cheul and Kang, Myoung Hee and Choi, In Sil and Ryu, Hye Won and Lee, Kyung Hee and Lee, Moon Hee and Lee, Ji Young and Park, Ji Hyun and Jeon, So-Yeon and Lee, Namsu and Park, Chi-Young and Kim, Yeul Hong},
  title = {Treatment Patterns and Prognosis of Palliative Chemotherapy Combined With Targeting Agents in Patients With Unresectable Metastatic Colorectal Cancer: CHOICE, A Multicenter Longitudinal Observational Study},
  journal = {Anticancer Research},
  year = {2024},
  doi = {10.21873/anticanres.16818}
}
Kostenlos starten →